vs

Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and Midland States Bancorp, Inc. (MSBI). Click either name above to swap in a different company.

4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $79.5M, roughly 1.1× Midland States Bancorp, Inc.). Midland States Bancorp, Inc. runs the higher net margin — 23.2% vs 22.8%, a 0.4% gap on every dollar of revenue. Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs -6.4%).

4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.

Rainier Bancorporation was the Seattle-based parent corporation of Rainier National Bank, a Washington state bank with branches throughout the state. Rainier traced its roots back to the National Bank of Commerce, which was founded by Richard Holyoke in 1889. The name Rainier National Bank was adopted in 1974. Rainier Bancorp expanded into Alaska with the purchase of Anchorage's People's Bank & Trust in 1983 and into Oregon with the purchase of Gresham's Mount Hood Security Bank in 1986, expa...

FDMT vs MSBI — Head-to-Head

Bigger by revenue
FDMT
FDMT
1.1× larger
FDMT
$85.1M
$79.5M
MSBI
Higher net margin
MSBI
MSBI
0.4% more per $
MSBI
23.2%
22.8%
FDMT
Faster 2-yr revenue CAGR
FDMT
FDMT
Annualised
FDMT
5412.6%
-6.4%
MSBI

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
FDMT
FDMT
MSBI
MSBI
Revenue
$85.1M
$79.5M
Net Profit
$19.4M
$18.5M
Gross Margin
Operating Margin
17.3%
Net Margin
22.8%
23.2%
Revenue YoY
8508900.0%
Net Profit YoY
139.1%
739.3%
EPS (diluted)
$0.43
$0.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FDMT
FDMT
MSBI
MSBI
Q1 26
$79.5M
Q4 25
$85.1M
$85.6M
Q3 25
$90.0K
$81.1M
Q2 25
$15.0K
$82.2M
Q1 25
$14.0K
$76.1M
Q4 24
$1.0K
$93.9M
Q3 24
$3.0K
$92.7M
Q2 24
$5.0K
$90.9M
Net Profit
FDMT
FDMT
MSBI
MSBI
Q1 26
$18.5M
Q4 25
$19.4M
$-2.9M
Q3 25
$-56.9M
$7.6M
Q2 25
$-54.7M
$12.0M
Q1 25
$-48.0M
$-141.0M
Q4 24
$-30.8M
Q3 24
$-43.8M
$20.4M
Q2 24
$-35.0M
$25.7M
Operating Margin
FDMT
FDMT
MSBI
MSBI
Q1 26
Q4 25
17.3%
-5.5%
Q3 25
-67983.3%
13.9%
Q2 25
-396373.3%
18.1%
Q1 25
-383007.1%
-181.2%
Q4 24
-66.5%
Q3 24
-1704400.0%
26.9%
Q2 24
-849120.0%
35.0%
Net Margin
FDMT
FDMT
MSBI
MSBI
Q1 26
23.2%
Q4 25
22.8%
-4.9%
Q3 25
-63195.6%
9.3%
Q2 25
-364386.7%
14.6%
Q1 25
-342657.1%
-185.4%
Q4 24
-52.5%
Q3 24
-1461433.3%
22.1%
Q2 24
-699060.0%
28.3%
EPS (diluted)
FDMT
FDMT
MSBI
MSBI
Q1 26
$0.74
Q4 25
$0.43
$-0.22
Q3 25
$-1.01
$0.24
Q2 25
$-0.98
$0.44
Q1 25
$-0.86
$-6.58
Q4 24
$-1.49
Q3 24
$-0.79
$0.83
Q2 24
$-0.63
$1.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FDMT
FDMT
MSBI
MSBI
Cash + ST InvestmentsLiquidity on hand
$402.7M
$89.4M
Total DebtLower is stronger
$33.2M
Stockholders' EquityBook value
$505.7M
$569.5M
Total Assets
$566.7M
$6.5B
Debt / EquityLower = less leverage
0.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FDMT
FDMT
MSBI
MSBI
Q1 26
$89.4M
Q4 25
$402.7M
$127.8M
Q3 25
$305.1M
$166.1M
Q2 25
$293.2M
$176.6M
Q1 25
$321.4M
$102.0M
Q4 24
$424.9M
$114.8M
Q3 24
$501.9M
$121.9M
Q2 24
$541.9M
$124.6M
Total Debt
FDMT
FDMT
MSBI
MSBI
Q1 26
$33.2M
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
FDMT
FDMT
MSBI
MSBI
Q1 26
$569.5M
Q4 25
$505.7M
$565.5M
Q3 25
$369.0M
$584.0M
Q2 25
$420.9M
$573.7M
Q1 25
$469.7M
$571.4M
Q4 24
$510.6M
$710.8M
Q3 24
$552.9M
$771.2M
Q2 24
$588.3M
$736.8M
Total Assets
FDMT
FDMT
MSBI
MSBI
Q1 26
$6.5B
Q4 25
$566.7M
$6.5B
Q3 25
$424.0M
$6.9B
Q2 25
$473.6M
$7.1B
Q1 25
$515.7M
$7.3B
Q4 24
$560.4M
$7.5B
Q3 24
$604.0M
$7.7B
Q2 24
$620.1M
$7.7B
Debt / Equity
FDMT
FDMT
MSBI
MSBI
Q1 26
0.06×
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FDMT
FDMT
MSBI
MSBI
Operating Cash FlowLast quarter
$28.6M
Free Cash FlowOCF − Capex
$28.5M
FCF MarginFCF / Revenue
33.5%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
1.47×
TTM Free Cash FlowTrailing 4 quarters
$-109.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FDMT
FDMT
MSBI
MSBI
Q1 26
Q4 25
$28.6M
$125.7M
Q3 25
$-46.5M
$80.0M
Q2 25
$-43.4M
$28.1M
Q1 25
$-47.8M
$24.7M
Q4 24
$-134.6M
$176.5M
Q3 24
$-29.4M
$46.5M
Q2 24
$-30.2M
$31.4M
Free Cash Flow
FDMT
FDMT
MSBI
MSBI
Q1 26
Q4 25
$28.5M
$120.3M
Q3 25
$-46.6M
$78.6M
Q2 25
$-43.4M
$26.7M
Q1 25
$-48.4M
$22.9M
Q4 24
$-138.4M
$169.6M
Q3 24
$-31.2M
$44.4M
Q2 24
$-30.6M
$29.9M
FCF Margin
FDMT
FDMT
MSBI
MSBI
Q1 26
Q4 25
33.5%
140.6%
Q3 25
-51765.6%
96.9%
Q2 25
-289620.0%
32.4%
Q1 25
-345635.7%
30.1%
Q4 24
-13837100.0%
180.6%
Q3 24
-1038966.7%
47.9%
Q2 24
-611840.0%
32.9%
Capex Intensity
FDMT
FDMT
MSBI
MSBI
Q1 26
Q4 25
0.1%
6.2%
Q3 25
101.1%
1.7%
Q2 25
440.0%
1.7%
Q1 25
4507.1%
2.4%
Q4 24
378600.0%
7.3%
Q3 24
59266.7%
2.3%
Q2 24
6980.0%
1.7%
Cash Conversion
FDMT
FDMT
MSBI
MSBI
Q1 26
Q4 25
1.47×
Q3 25
10.58×
Q2 25
2.33×
Q1 25
Q4 24
Q3 24
2.28×
Q2 24
1.22×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FDMT
FDMT

Segment breakdown not available.

MSBI
MSBI

Net Interest Income$57.4M72%
Noninterest Income$22.1M28%

Related Comparisons